Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
Jennifer A RymerSonia S AnandEike Sebastian DebusLloyd P HaskellConnie N HessW Schuyler JonesEva MuehlhoferScott D BerkowitzRupert M BauersachsMarc P BonacaManesh R PatelPublished in: Circulation (2023)
Rivaroxaban added to aspirin or dual antiplatelet therapy after LER for peripheral artery disease reduces ischemic risk and increases major bleeding without an increased risk of intracranial or fatal bleeding. These benefits are consistent in those treated with endovascular and surgical approaches with significant benefits for major adverse limb events. These data support the use of rivaroxaban in addition to aspirin or dual antiplatelet therapy after endovascular intervention for symptomatic peripheral artery disease.
Keyphrases
- antiplatelet therapy
- peripheral artery disease
- percutaneous coronary intervention
- atrial fibrillation
- acute coronary syndrome
- venous thromboembolism
- pulmonary embolism
- coronary artery bypass grafting
- randomized controlled trial
- coronary artery disease
- low dose
- aortic dissection
- electronic health record
- type diabetes
- big data
- cardiovascular disease
- ischemia reperfusion injury
- machine learning
- brain injury
- data analysis
- deep learning